Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P06889 (
Mol
)
630,302
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Deficiency of huntingtin-interacting protein 1 (Hip1) results in degenerative phenotypes. Here we generated a
Hip1
deficiency allele where a floxed transcriptional stop cassette and a human
HIP1
cDNA were knocked into intron 1 of the mouse
Hip1
locus.
CMV-Cre
-mediated germ line excision of the stop cassette resulted in expression of HIP1 and rescue of the
Hip1
knockout phenotype.
Mx1-Cre
-mediated excision led to HIP1 expression in spleen, kidney and liver, and also rescued the phenotype. In contrast,
hGFAP-Cre
-mediated, brain-specific HIP1 expression did not rescue the phenotype. Metabolomics and microarrays of several
Hip1
knockout tissues identified low phosphocholine (PC) levels and low
glycerophosphodiester phosphodiesterase domain containing 3
(Gdpd3) gene expression. Since Gdpd3 has lysophospholipase D activity that results in the formation of choline, a precursor of PC,
Gdpd3
downregulation could lead to the low PC levels. To test whether
Gdpd3
contributes to the
Hip1
deficiency phenotype, we generated
Gdpd3
knockout mice. Double knockout of
Gdpd3
and
Hip1
worsened the Hip1 phenotype. This suggests that Gdpd3 compensates for Hip1 loss. More-detailed knowledge of how
Hip1
deficiency leads to low PC will improve our understanding of HIP1 in choline metabolism in normal and disease states.
Mol
Cell Biol 2018 12 01
PMID:Deficiency of the Endocytic Protein Hip1 Leads to Decreased
Gdpd3
Expression, Low Phosphocholine, and Kypholordosis. 3022 18